Aviva Systems Biology Corp.

IN VITRO DIAGNOSTICS Financings Vermillion Inc. Vermillion Inc. grossed $5.6mm through the private sale of 3.75mm common shares at $1.40 (a 6% premium). Investors also received five-year warrants

Modulating ion channels via accessory proteins PO Box 2299 Bristol BS99 5YG, UK Phone: (44) 117 928 8973 Fax: (44) 117 925 2659 Web Site: www.lectustherapeutics.com Contact: Roland Kozlowski, PhD,

Automated medium- and high-throughput ion channel screening systems promise to jump start the search for ion channel modulating drugs, a vast and promising area of drug discovery. In Vivo Europe Rx lo

The high-throughput revolution passed by this once-fertile drug discovery territory. Will new technologies now allow researchers to take a second, more productive look? By Marc Wortman In a talk at th